Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
PubWeight™: 0.79‹?›
Published in Circulation on August 05, 2016
Authors
Michael D Ezekowitz1, Rangadham Nagarakanti2, Herbert Noack2, Martina Brueckmann2, Claire Litherland2, Mark Jacobs2, Andreas Clemens2, Paul A Reilly2, Stuart J Connolly2, Salim Yusuf2, Lars Wallentin2
Author Affiliations
1: From Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA (M.D.E.); Cardiovascular Research Foundation, New York, NY (M.D.E., C.L.); Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ (R.N.); Electrophysiology Research Foundation, Warren, NJ (R.N.); Boehringer Ingelheim GmbH & Co, Ingelheim am Rhein, Germany (H.N., M.B.); Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany (M.B.); Albert Einstein College of Medicine, New York, NY (M.J.); Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany (A.C.); Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT (P.A.R.); McMaster University, Hamilton, Canada (S.J.C., S.Y.); and Uppsala Clinical Research Center, Uppsala, Sweden (L.W.). michael.ezekowitz@comcast.net.
2: From Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA (M.D.E.); Cardiovascular Research Foundation, New York, NY (M.D.E., C.L.); Rutgers-Robert Wood Johnson Medical School, Piscataway, NJ (R.N.); Electrophysiology Research Foundation, Warren, NJ (R.N.); Boehringer Ingelheim GmbH & Co, Ingelheim am Rhein, Germany (H.N., M.B.); Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany (M.B.); Albert Einstein College of Medicine, New York, NY (M.J.); Center for Thrombosis and Hemostasis, University Medical Center Mainz, Germany (A.C.); Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT (P.A.R.); McMaster University, Hamilton, Canada (S.J.C., S.Y.); and Uppsala Clinical Research Center, Uppsala, Sweden (L.W.).